FOSAVANCE

This brand name is authorized in Austria, Canada, Croatia, Cyprus, Finland, France, Germany, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug FOSAVANCE contains a combination of these active pharmaceutical ingredients (APIs):

1	Alendronate sodium trihydrate UNII 2UY4M2U3RA - ALENDRONATE SODIUM
	Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.
	Read more about Alendronic acid
2	Vitamin D3 UNII 1C6V77QF41 - CHOLECALCIFEROL
	In its biologically active form vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated.
	Read more about Vitamin D3

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FOSAVANCE Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M05BB03	Alendronic acid and colecalciferol	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02276429, 02314940
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00968730, 00968747, 03420286, 05703143, 14340745, 15241442, 17531032
EE	Ravimiamet	1213344, 1213355, 1213366, 1213377, 1339130, 1339141, 1339152
ES	Centro de información online de medicamentos de la AEMPS	05310002, 05310002IP, 05310007, 05310007IP, 05310007IP1
FI	Lääkealan turvallisuus- ja kehittämiskeskus	025306, 112368
FR	Base de données publique des médicaments	63591602, 68300050
GB	Medicines & Healthcare Products Regulatory Agency	142406, 161821, 374381, 95239
IE	Health Products Regulatory Authority	26112, 37152, 75212, 75251, 75279, 75315, 75318, 75323, 75333, 75382
IL	מִשְׂרַד הַבְּרִיאוּת	6305
IT	Agenzia del Farmaco	036845028, 036845079
LT	Valstybinė vaistų kontrolės tarnyba	1004487, 1004488, 1004806, 1005111, 1028603, 1028604, 1028606, 1028607
NL	Z-Index G-Standaard, PRK	122424, 122432
PL	Rejestru Produktów Leczniczych	100143587, 100309770
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67694001, W67694002, W67694003, W67694004, W67697001, W67697002, W67697003
TN	Direction de la Pharmacie et du Médicament	3443032
TR	İlaç ve Tıbbi Cihaz Kurumu	8683280337190, 8683280337206
ZA	Health Products Regulatory Authority	44/3.2/0350, A40/3.2/0259